Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774914 · ClinicalTrials.gov registry record
LEMTRADA Pregnancy Registry in Multiple Sclerosis
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 42
- Enrollment target
NCT03774914: Completed study, sponsored by Genzyme, a Sanofi Company.
NCT03774914 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03774914 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Primary Objective: The primary goal of this registry is to assess the risk of spontaneous abortion in prospective enrolled women exposed to LEMTRADA for multiple sclerosis. Secondary Objective: The secondary goals of this registry is to assess maternal, fetal and infant outcome in women with multiple sclerosis, exposed to LEMTRADA.
Primary Outcome
Number and rate of spontaneous abortions on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Interventions
- DRUG Alemtuzumab (GZ402673)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2021-11-22 |
What the finished NCT03774914 record still lists
NCT03774914 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Alemtuzumab (GZ402673) is the first listed.
NCT03774914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03774914 about?
NCT03774914 is a clinical study titled "LEMTRADA Pregnancy Registry in Multiple Sclerosis". Primary Objective: The primary goal of this registry is to assess the risk of spontaneous abortion in prospective enrolled women exposed to LEMTRADA for multiple sclerosis. Secondary Objective: The secondary goals of this registry is to assess maternal, fetal and infant outcome in women with mult...
What is the current status of trial NCT03774914?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-09-01. Estimated completion is 2021-11-22.
What interventions are being tested in trial NCT03774914?
The interventions under investigation include: Alemtuzumab (GZ402673) (DRUG).
Who is sponsoring clinical trial NCT03774914?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI